Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

Explainable AI Dermoscopy Tool Supports Risk Assessment for Skin Cancer

By HospiMedica International staff writers
Posted on 26 Oct 2026

Skin lesions can be difficult to triage when benign and malignant findings share visual features, leaving clinicians uncertain about whether to recommend biopsy or continued monitoring. More...

These decisions require balancing the procedural burden of biopsy with the potential consequences of delayed cancer diagnosis. To support this assessment, Mayo Clinic researchers have evaluated an AI tool designed to assist dermatologists in assessing lesion risk.

The technology, called Dermoscopy Explainable Intelligence (DEXI), was evaluated by Mayo Clinic researchers as part of an advanced imaging system used to capture and track skin lesions over time. DEXI assigns each lesion a cancer-risk score from 0.0 to 10.0. It also identifies image features such as asymmetry, border and color that contributed to the score.

DEXI is a deep-learning tool trained on more than 66,000 annotated dermoscopy images. Its explainable artificial intelligence approach shows clinicians which visual characteristics influenced the risk assessment, allowing dermatologists to consider both the score and associated features alongside their clinical evaluation.

The retrospective study included 178 patients who underwent total-body photography, sequential digital dermoscopy imaging, and subsequent biopsy of one or more skin lesions. Researchers analyzed 261 lesions with both a DEXI score and a tissue-confirmed diagnosis, comparing noncancerous lesions with melanoma and nonmelanoma skin cancers.

At a threshold of 3.0, with scores at or above this value considered positive for potential skin cancer, DEXI correctly identified 93.4% of cancerous lesions and 75% of noncancerous lesions. Scores also differed by diagnosis: the average was 2.5 for noncancerous lesions, compared with 7.8 for nonmelanoma skin cancers and 6.0 for melanomas.

The findings were published in Mayo Clinic Proceedings on October 21, 2026. The researchers identified 3.0 as a potential threshold to help inform decisions about monitoring or biopsy. They also noted that DEXI does not account for patient-specific factors such as age, medications and history of melanoma, and that it was less effective for severely atypical nevi, or skin moles, and early evolving melanomas.

“Prior to the study, I would review a patient's DEXI score, but I wouldn't know exactly what to do with the number. Now I can confidently use the score as another piece of data to inform my clinical judgment on whether I recommend a biopsy or monitoring,” said Jenny Link, M.D., a dermatologist at Mayo Clinic and the study's lead author.

“Our study demonstrated that DEXI is a useful and valuable tool to support clinicians as they evaluate cancerous and noncancerous skin lesions, but it should not be used in isolation. The score must be interpreted alongside clinical findings and patient-specific factors, and the tool requires further validation and refinement,” added Link.

Related Links
Mayo Clinic


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Wound Irrigation Solution
Prontosan®
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: Shutterstock

AI-Derived Heart Age Linked to Cardiovascular and Dementia-Related Mortality

Cardiovascular disease is increasingly associated with dementia-related mortality and other forms of age-related decline. Identifying people with greater long-term vulnerability before severe outcomes... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.